Medications in the treatment of borderline personality disorder 2006

Current Psychiatry Reports

Volumn 9, Issue 1, 2007, Pages 53-62

  Mercer, Deanna ^a  

^a UNIVERSITY OF OTTAWA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

AMITRIPTYLINE; ARIPIPRAZOLE; BENZODIAZEPINE; CARBAMAZEPINE; CLOZAPINE; DESIPRAMINE; FLUOXETINE; FLUPENTIXOL; FLUVOXAMINE; HALOPERIDOL; IMIPRAMINE; LAMOTRIGINE; LITHIUM SALT; NORADRENALIN UPTAKE INHIBITOR; NORTRIPTYLINE; OLANZAPINE; OMEGA 3 FATTY ACID; PHENYLZINE; PLACEBO; REBOXITINE; RISPERIDONE; SEROTONIN UPTAKE INHIBITOR; TOPIRAMATE; TRANYLCYPROMINE; TRICYCLIC ANTIDEPRESSANT AGENT; TRIFLUOPERAZINE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VALPROATE SEMISODIUM; VENLAFAXINE; ZIPRASIDONE;

AGGRESSION; ANGER; ANXIETY; BORDERLINE STATE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DEPRESSION; DIZZINESS; DRUG EFFICACY; DRUG MEGADOSE; DRUG WITHDRAWAL; ELECTROCONVULSIVE THERAPY; EVIDENCE BASED MEDICINE; HAMILTON SCALE; HUMAN; HUMAN RELATION; HYPERSALIVATION; LOW DRUG DOSE; MONOTHERAPY; NEUTROPENIA; PSYCHOLOGICAL RATING SCALE; PSYCHOTHERAPY; REVIEW; SEDATION; SIDE EFFECT; SOMATIZATION; SUICIDAL IDEATION; SYSTEMATIC REVIEW; TREATMENT DURATION; WEIGHT GAIN;

AGGRESSION; ANTIDEPRESSIVE AGENTS; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; BORDERLINE PERSONALITY DISORDER; DEPRESSION; ELECTROCONVULSIVE THERAPY; HUMANS; SEROTONIN UPTAKE INHIBITORS;

EID: 33846943692     PISSN: 15233812     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11920-007-0010-1     Document Type: Review

References (75)

1. Zanarini MC, Frankenburg FR, Khera GS, Bleichmar J: Treatment histories of borderline inpatients. Compr Psychiatry 2001, 42:144-150.
2. American Psychiatric Association Practice Guidelines: Practice guideline for the treatment of patients with borderline personality disorder. American Psychiatric Association. Am J Psychiatry 2001, 158(10 Suppl):1-52.
3. Box G, Hunter W, Hunter J: Statistics for Experimenters, an Introduction to Design, Data Analysis and Model Building. New York: John Wiley & Sons; 1978:319.
4. Cornelius JR, Soloff PH, Perel JM, Ulrich RF: A preliminary trial of fluoxetine in refractory borderline patients. J Clin Psychopharmacol 1991, 11:116-120.
5. Coccaro EF, Astill JL, Herbert JL, Schut AG: Fluoxetine treatment of impulsive aggression in DSM-III-R personality disorder patients. J Clin Psychopharmacol 1990, 10:373-375.
6. Norden MJ: Fluoxetine in borderline personality disorder. Prog Neuropsychopharmacol Biol Psychiatry 1989, 13:885-893.
7. Markovitz PJ, Calabrese JR, Schulz SC, Meltzer HY: Fluoxetine in the treatment of borderline and schizotypal personality disorders. Am J Psychiatry 1991, 148:1064-1067.
8. Joyce PR, Mulder RT, Luty SE, et al.: Borderline personality disorder in major depression: symptomatology, temperament, character, differential drug response, and 6-month outcome. Compr Psychiatry 2003, 44:35-43.
9. Markovitz PJ, Wagner SC: Venlafaxine in the treatment of borderline personality disorder. Psychopharmacol Bull 1995, 31:773-777.
10. Simpson EB, Yen S, Costello E, et al.: Combined dialectical behavior therapy and fluoxetine in the treatment of borderline personality disorder. J Clin Psychiatry 2004, 65:379-385.
11. Bellino S, Zizza M, Rinaldi C, Bogetto F: Combined treatment of major depression in patients with borderline personality disorder: a comparison with pharmacotherapy. Can J Psychiatry 2006, 51:453-460.
12. Coccaro EF, Kavoussi RJ: Fluoxetine and impulsive aggressive behavior in personality-disordered subjects. Arch Gen Psychiatry 1997, 54:1081-1088.
13. Rinne T, van den Brink W, Wouters L, van Dyck R: SSRI treatment of borderline personality disorder: a randomized, placebo-controlled clinical trial for female patients with borderline personality disorder [see comment]. Am J Psychiatry 2002, 159:2048-2054.
14. Salzman C, Wolfson AN, Schatzberg A, et al.: Effect of fluoxetine on anger in symptomatic volunteers with borderline personality disorder. J Clin Psychopharmacol 1995, 15:23-29.
15. Soloff PH, George A, Nathan S, et al.: Amitriptyline versus haloperidol in borderlines: final outcomes and predictors of response. J Clin Psychopharmacol 1989, 9:238-246.
16. Parsons B, Quitkin FM, McGrath PJ, et al.: Phenelzine, imipramine, and placebo in borderline patients meeting criteria for atypical depression. Psychopharmacol Bull 1989, 25:524-534.
17. Soloff PH, Cornelius J, George A, et al.: Efficacy of phenelzine and haloperidol in borderline personality disorder. Arch Gen Psychiatry 1993, 50:377-385.
18. Links PS, Steiner M, Boiago I, Irwin D: Lithium therapy for borderline patients: preliminary findings. J Personal Disord 1990, 4:173-181.
19. Klein DF: Importance of psychiatric diagnosis in prediction of clinical drug effects. Arch Gen Psychiatry 1967, 16:118-126.
20. Montgomery SA, Montgomery D: Pharmacological prevention of suicidal behaviour. J Affect Disord 1982, 4:291-298.
21. Cowdry RW, Gardner DL: Pharmacotherapy of borderline personality disorder. Alprazolam, carbamazepine, trifluoperazine, and tranylcypromine. Arch Gen Psychiatry 1988, 45:111-119.
22. Anghelescu I, Janen B, Schindler F, Lammers CH: Worsening of borderline symptoms under reboxetine treatment. J Neuropsychiatry Clin Neurosci 2005, 17:559-560.
23. Soler J, Pascual JC, Campins J, et al.: Double-blind, placebo-controlled study of dialectical behavior therapy plus olanzapine for borderline personality disorder. Am J Psychiatry 2005, 162:1221-1224.
24. Zanarini MC, Frankenburg FR: Olanzapine treatment of female borderline personality disorder patients: a double-blind, placebo-controlled pilot study [see comment]. J Clin Psychiatry 2001, 62:849-854.
25. Bogenschutz MP, George Nurnberg H: Olanzapine versus placebo in the treatment of borderline personality disorder. J Clin Psychiatry 2004, 65:104-109.
26. Zanarini MC, Frankenburg FR, Parachini EA: A preliminary, randomized trial of fluoxetine, olanzapine, and the olanzapine-fluoxetine combination in women with borderline personality disorder. J Clin Psychiatry 2004, 65:903-907.
27. Khouzam HR, Donnelly NJ: Remission of self-mutilation in a patient with borderline personality during risperidone therapy. J Nerv Ment Dis 1997, 185:348-349.
28. Rocca P, Marchiaro L, Cocuzza E, Bogetto F: Treatment of borderline personality disorder with risperidone [see comment]. J Clin Psychiatry 2002, 63:241-244.
29. Schulz SC: A double-blind study of risperidone for borderline personality disorder. New Research Abstracts. Annual Meeting of the American Psychiatric Association, 1998. Toronto, Ontario: American Psychiatric Association; 1998.
30. Schulz SC, Camlin KL, Berry SA, Jesberger JA: Olanzapine safety and efficacy in patients with borderline personality disorder and comorbid dysthymia. Biol Psychiatry 1999, 46:1429-1435.
31. Nickel MK, Muehlbacher M, Nickel C, et al.: Aripiprazole in the treatment of patients with borderline personality disorder: a double-blind, placebo-controlled study. Am J Psychiatry 2006, 163:833-838.
32. Pascual JC, Otter S, Soler J, et al.: Ziprasidone in the acute treatment of borderline personality disorder in psychiatric emergency services. J Clin Psychiatry 2004, 65:1281-1282.
33. Pascual JC, Madre M, Soler J, et al.: Injectable atypical antipsychotics for agitation in borderline personality disorder. Pharmacopsychiatry 2006, 39:117-118.
34. Ferreri MM, Loze JY, Rouillon F, Limosin F: Clozapine treatment of a borderline personality disorder with severe self-mutilating behaviours. Eur Psychiatry 2004, 19:177-178. [Published erratum appears in Eur Psychiatry 2004, 19:393.]
35. Steinert T, Schmidt-Michel PO, Kaschka WP: Considerable improvement in a case of obsessive-compulsive disorder in an emotionally unstable personality disorder, borderline type under treatment with clozapine. Pharmacopsychiatry 1996, 29:111-114.
36. Benedetti F, Sforzini L, Colombo C, et al.: Low-dose clozapine in acute and continuation treatment of severe borderline personality disorder. J Clin Psychiatry 1998, 59:103-107.
37. Chengappa KN, Ebeling T, Kang JS, et al.: Clozapine reduces severe self-mutilation and aggression in psychotic patients with borderline personality disorder. J Clin Psychiatry 1999, 60:477-484.
38. Frankenburg FR, Zanarini MC: Clozapine treatment of borderline patients: a preliminary study. Compr Psychiatry 1993, 34:402-405.
39. Hilger E, Barnas C, Kasper S: Quetiapine in the treatment of borderline personality disorder. World J Biol Psychiatry 2003, 4:42-44.
40. Bellino S, Paradiso E, Bogetto F: Efficacy and tolerability of quetiapine in the treatment of borderline personality disorder: a pilot study. J Clin Psychiatry 2006, 67:1042-1046.
41. Goldberg SC, Schulz SC, Schulz PM, et al.: Borderline and schizotypal personality disorders treated with low-dose thiothixene vs placebo. Arch Gen Psychiatry 1986, 43:680-686.
42. Leone NF: Response of borderline patients to loxapine and chlorpromazine. J Clin Psychiatry 1982, 43:148-150.
43. Serban G, Siegel S: Response of borderline and schizotypal patients to small doses of thiothixene and haloperidol. Am J Psychiatry 1984, 141:1455-1458.
44. de la Fuente JM, Lotstra F: A trial of carbamazepine in borderline personality disorder. Eur Neuropsychopharmacol 1994, 4:479-486.
45. Bellino S, Paradiso E, Bogetto F: Oxcarbazepine in the treatment of borderline personality disorder: a pilot study. J Clin Psychiatry 2005, 66:1111-1115.
46. Hollander E, Allen A, Lopez RP, et al.: A preliminary double-blind, placebo-controlled trial of divalproex sodium in borderline personality disorder. J Clin Psychiatry 2001, 62:199-203.
47. Frankenburg FR, Zanarini MC: Divalproex sodium treatment of women with borderline personality disorder and bipolar II disorder: a double-blind placebo-controlled pilot study. J Clin Psychiatry 2002, 63:442-446.
48. Hollander E, Tracy KA, Swann AC, et al.: Divalproex in the treatment of impulsive aggression: efficacy in cluster B personality disorders. Neuropsychopharmacology 2003, 28:1186-1197.
49. Pinto OC, Akiskal HS: Lamotrigine as a promising approach to borderline personality: an open case series without concurrent DSM-IV major mood disorder. J Affect Disord 1998, 51:333-343.
50. Tritt K, Nickel C, Lahmann C, et al.: Lamotrigine treatment of aggression in female borderline-patients: a randomized, double-blind, placebo-controlled study. J Psychopharmacol 2005, 19:287-291.
51. Rifkin A, Quitkin F, Carrillo C, et al.: Lithium carbonate in emotionally unstable character disorder. Arch Gen Psychiatry 1972, 27:519-523.
52. Cassano P, Lattanzi L, Pini S, et al.: Topiramate for self-mutilation in a patient with borderline personality disorder [comment]. Bipolar Disord 2001, 3:161.
53. Nickel MK, Nickel C, Mitterlehner FO, et al.: Topiramate treatment of aggression in female borderline personality disorder patients: a double-blind, placebo-controlled study. J Clin Psychiatry 2004, 65:1515-1519.
54. Nickel MK, Nickel C, Kaplan P, et al.: Treatment of aggression with topiramate in male borderline patients: a double-blind, placebo-controlled study. Biol Psychiatry 2005, 57:495-499.
55. Loew TH, Nickel MK, Muehlbacher M, et al.: Topiramate treatment for women with borderline personality disorder. J Clin Psychopharmacol 2006, 21:61-66.
56. Faltus FJ: The positive effect of alprazolam in the treatment of three patients with borderline personality disorder. Am J Psychiatry 1984, 141:802-803.
57. Vorma H, Naukkarinen HH, Sarna SJ, Kuoppasalmi KI: Predictors of benzodiazepine discontinuation in subjects manifesting complicated dependence. Subst Use Misuse 2005, 40:499-510.
58. Philipsen A, Richter H, Schmahl C, et al.: Clonidine in acute aversive inner tension and self-injurious behavior in female patients with borderline personality disorder. J Clin Psychiatry 2004, 65:1414-1419.
59. Feske U, Mulsant BH, Pilkonis PA, et al.: Clinical outcome of ECT in patients with major depression and comorbid borderline personality disorder [see comment]. Am J Psychiatry 2004, 161:2073-2080.
60. Barrett RP, Feinstein C, Hole WT: Effects of naloxone and naltrexone on self-injury: a double-blind, placebo-controlled analysis. Am J Ment Retard 1989, 93:644-651.
61. Herman BH, Hammock MK, Arthur-Smith A, et al.: Naltrexone decreases self-injurious behavior. Ann Neurol 1987, 22:550-552.
62. Griengl H, Sendera A, Dantendorfer K: Naltrexone as a treatment of self-injurious behavior - a case report. Acta Psychiatr Scand 2001, 103:234-236.
63. Roth AS, Ostroff RB, Hoffman RE: Naltrexone as a treatment for repetitive self-injurious behaviour: an open-label trial. J Clin Psychiatry 1996, 57:233-237.
64. Sonne S, Rubey R, Brady K, et al.: Naltrexone treatment of self-injurious thoughts and behaviors. J Nerv Ment Dis 1996, 184:192-195.
65. Bohus MJ, Landwehrmeyer GB, Stiglmayr CE, et al.: Naltrexone in the treatment of dissociative symptoms in patients with borderline personality disorder: an open-label trial. J Clin Psychiatry 1999, 60:598-603.
66. Philipsen A, Schmahl C, Lieb K: Naloxone in the treatment of acute dissociative states in female patients with borderline personality disorder. Pharmacopsychiatry 2004, 37:196-199.
67. Zanarini MC, Frankenburg FR: Omega-3 fatty acid treatment of women with borderline personality disorder: a double-blind, placebo-controlled pilot study. Am J Psychiatry 2003, 160:167-169.
68. Koons CR, Robins CJ, Tweed J, et al.: Efficacy of dialectical behavior therapy in women veterans with borderline personality disorder. Behav Ther 2001, 32:371-390.
69. Linehan MM, Armstrong HE, Suarez A, et al.: Cognitive-behavioral treatment of chronically parasuicidal borderline patients. Arch Gen Psychiatry 1991, 48:1060-1064.
70. Linehan MM, Comtois KA, Murray AM, et al.: Two-year randomized controlled trial and follow-up of dialectical behavior therapy vs therapy by experts for suicidal behaviors and borderline personality disorder. Arch Gen Psychiatry 2006, 63:757-766.
71. Linehan MM, Dimeff LA, Reynolds SK, et al.: Dialectical behavior therapy versus comprehensive validation therapy plus 12-step for the treatment of opioid dependent women meeting criteria for borderline personality disorder. Drug Alcohol Depend 2002, 67:13-26.
72. Linehan MM, Schmidt H 3rd, Dimeff LA, et al.: Dialectical behavior therapy for patients with borderline personality disorder and drug-dependence. Am J Addict 1999, 8:279-292.
73. Turner RM: Naturalistic evaluation of dialectical behavior therapy-oriented treatment for borderline personality disorder. Cogn Behav Pract 2000, 7:413-419.
74. Verheul R, Van Den Bosch LM, Koeter MW, et al.: Dialectical behaviour therapy for women with borderline personality disorder: 12-month, randomised clinical trial in The Netherlands [see comment]. Br J Psychiatry 2003, 182:135-140.
75. Bateman A, Fonagy P: Treatment of borderline personality disorder with psychoanalytically oriented partial hospitalization: an 18-month follow-up. Am J Psychiatry 2001, 158:36-42.